JELMYTO is a Kit in the Human Prescription Drug category. It is labeled and distributed by Cenexi - Bla. The primary component is .
| Product ID | 69605-103_d44ffd1f-d257-4d1a-e053-2a95a90a024c | 
| NDC | 69605-103 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | JELMYTO | 
| Generic Name | Mitomycin | 
| Dosage Form | Kit | 
| Marketing Start Date | 2020-05-01 | 
| Marketing Category | NDA / | 
| Application Number | NDA211728 | 
| Labeler Name | CENEXI - BLA | 
| Active Ingredient Strength | 0 | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2022-12-31 | 
| Marketing Start Date | 2020-05-01 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 69605-103 | JELMYTO | mitomycin | 
| 72493-103 | JELMYTO | JELMYTO | 
| 0143-9135 | Mitomycin | Mitomycin | 
| 0143-9136 | Mitomycin | Mitomycin | 
| 0143-9279 | Mitomycin | Mitomycin | 
| 0143-9280 | Mitomycin | Mitomycin | 
| 16729-108 | Mitomycin | Mitomycin | 
| 16729-115 | Mitomycin | Mitomycin | 
| 16729-116 | Mitomycin | Mitomycin | 
| 16729-246 | Mitomycin | Mitomycin | 
| 16729-247 | Mitomycin | Mitomycin | 
| 16729-248 | Mitomycin | Mitomycin | 
| 67457-518 | Mitomycin | Mitomycin | 
| 67457-519 | Mitomycin | Mitomycin | 
| 67457-520 | Mitomycin | Mitomycin | 
| 67457-995 | Mitomycin | Mitomycin | 
| 67457-996 | Mitomycin | Mitomycin | 
| 67457-997 | Mitomycin | Mitomycin | 
| 68001-389 | Mitomycin | Mitomycin | 
| 68001-390 | Mitomycin | Mitomycin | 
| 68001-391 | Mitomycin | Mitomycin | 
| 68083-483 | MITOMYCIN | MITOMYCIN | 
| 68083-484 | MITOMYCIN | MITOMYCIN | 
| 68083-502 | MITOMYCIN | MITOMYCIN | 
| 71288-137 | MITOMYCIN | MITOMYCIN | 
| 71288-138 | MITOMYCIN | MITOMYCIN | 
| 49771-002 | Mitosol | mitomycin | 
| 69448-001 | MUTAMYCIN | Mitomycin | 
| 69448-002 | MUTAMYCIN | Mitomycin | 
| 69448-003 | MUTAMYCIN | Mitomycin | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  JELMYTO  88204510  not registered Live/Pending | UROGEN PHARMA LTD. 2018-11-25 |